Log in

AKTS Aktis Oncology, Inc. NASDAQ · United States

Aktis Oncology (AKTS) news AKTS IPO and offering news

Latest Aktis Oncology news

We have not published a story on Aktis Oncology yet. When there is news, it will appear here.

Questions about Aktis Oncology

When did Aktis Oncology go public?

Our latest story on this, dated Jan 8, 2026: "Aktis Oncology prices upsized IPO at $18, raising about $318 million". The story links the filing or release it is based on. Read the story.

Has Aktis Oncology raised money recently?

Our latest story on this, dated Jan 8, 2026: "Aktis Oncology prices upsized IPO at $18, raising about $318 million". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Aktis Oncology?

Aktis Oncology, Inc. trades under the ticker AKTS on NASDAQ.

Where is Aktis Oncology listed?

Aktis Oncology, Inc. is listed on NASDAQ.

What is the SEC CIK of Aktis Oncology?

The SEC Central Index Key (CIK) for Aktis Oncology, Inc. is 2035832. Its filings are on SEC EDGAR.

Which country or territory is Aktis Oncology listed under?

Our directory records Aktis Oncology, Inc. under United States.

What does Aktis Oncology do?

Our directory classifies Aktis Oncology, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Aktis Oncology?

The ISIN recorded for Aktis Oncology, Inc. is US01021M1045.

Does aibio.space cover Aktis Oncology?

aibio.space lists Aktis Oncology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Aktis Oncology incorporated?

SEC records list its state or country of incorporation as DE.

What is the latest Aktis Oncology (AKTS) stock news?

Our latest story on Aktis Oncology, dated Jan 8, 2026: "Aktis Oncology prices upsized IPO at $18, raising about $318 million". The radiopharmaceutical developer sold 17.65 million shares on the Nasdaq, the first U.S. biotech IPO of 2026, after raising its offering size. Source.

How long will Aktis Oncology's cash last?

From our story of Jan 8, 2026: It had $246.2 million in cash at the end of September 2025, and Fierce said the IPO proceeds are expected to fund operations into the first half of 2028. Source.

How much cash does Aktis Oncology have?

From our story of Jan 8, 2026: It had $246.2 million in cash at the end of September 2025, and Fierce said the IPO proceeds are expected to fund operations into the first half of 2028. Source.

Is Aktis Oncology a smaller reporting company?

SEC records list Aktis Oncology, Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company.

Where is Aktis Oncology headquartered?

SEC records list its business address as 17 DRYDOCK AVENUE, BOSTON, MA, 02210.

Investor discussion: Aktis Oncology

Members talk about Aktis Oncology (AKTS). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Aktis Oncology, newest first. Each line links the filing it comes from.

  1. Distress

    Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source

  2. Financings

    Filed a final prospectus for a securities offering. SEC Form 424B4. Source

  3. Financings

    Filed a registration statement for a share offering. SEC Form S-1. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:AKTS on TradingView.

SEC filings and registration

SEC name
Aktis Oncology, Inc.
CIK
2035832
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
AKTS (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Business address
17 DRYDOCK AVENUE, BOSTON, MA, 02210
Phone
978-237-4380

Recent filings (8-K and 6-K are the company's own announcements)

  • 10-Q filed 2026-08-13
  • 8-K filed 2026-08-13
  • 10-Q filed 2026-05-11
  • 8-K filed 2026-05-11
  • 8-K filed 2026-04-16
  • 8-K filed 2026-03-30
  • 10-K filed 2026-03-30
  • 8-K filed 2026-01-12

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Aktis Oncology, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AKTS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Aktis Oncology, Inc.
Ticker
AKTS
Listing
NASDAQ
Country or territory
United States
Business scope
Pharmaceuticals: Major
ISIN
US01021M1045
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.